MX368838B - Administracion sublingual de riluzol. - Google Patents
Administracion sublingual de riluzol.Info
- Publication number
- MX368838B MX368838B MX2017006446A MX2017006446A MX368838B MX 368838 B MX368838 B MX 368838B MX 2017006446 A MX2017006446 A MX 2017006446A MX 2017006446 A MX2017006446 A MX 2017006446A MX 368838 B MX368838 B MX 368838B
- Authority
- MX
- Mexico
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- disclosed
- formulation
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004181 riluzole Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010031009 Oral pain Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017006446A MX2017006446A (es) | 2018-02-12 |
| MX368838B true MX368838B (es) | 2019-10-18 |
Family
ID=55085882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006446A MX368838B (es) | 2014-11-21 | 2015-11-17 | Administracion sublingual de riluzol. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (enExample) |
| EP (3) | EP3616686B8 (enExample) |
| JP (3) | JP6753860B2 (enExample) |
| KR (2) | KR102580378B1 (enExample) |
| CN (1) | CN107249567B (enExample) |
| AU (2) | AU2015350148B2 (enExample) |
| BR (1) | BR112017010423B1 (enExample) |
| CA (1) | CA2967662A1 (enExample) |
| CY (1) | CY1122469T1 (enExample) |
| DK (1) | DK3220891T3 (enExample) |
| EA (1) | EA038518B1 (enExample) |
| ES (2) | ES2751300T3 (enExample) |
| HR (1) | HRP20191892T8 (enExample) |
| HU (1) | HUE046869T2 (enExample) |
| IL (2) | IL278188B2 (enExample) |
| LT (1) | LT3220891T (enExample) |
| MX (1) | MX368838B (enExample) |
| PH (1) | PH12017500934B1 (enExample) |
| PL (1) | PL3220891T3 (enExample) |
| PT (1) | PT3220891T (enExample) |
| RS (1) | RS59490B1 (enExample) |
| SG (1) | SG11201703896QA (enExample) |
| SI (1) | SI3220891T1 (enExample) |
| WO (1) | WO2016081472A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017341723B2 (en) | 2016-10-11 | 2021-12-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| JP7354123B2 (ja) * | 2018-02-21 | 2023-10-02 | エイアイ・セラピューティクス・インコーポレーテッド | アピリモドとグルタミン酸作動薬を用いた併用療法 |
| KR20210024475A (ko) * | 2018-05-27 | 2021-03-05 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도 |
| EA202190544A1 (ru) * | 2018-08-16 | 2021-06-18 | Биохэйвен Терапьютикс Лтд. | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний |
| CA3158411A1 (en) * | 2019-10-22 | 2021-04-29 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
| PE20231204A1 (es) | 2020-05-09 | 2023-08-17 | Arvinas Operations Inc | Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| US20240000808A1 (en) | 2020-11-16 | 2024-01-04 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| JP3233638B2 (ja) | 1993-07-09 | 2001-11-26 | アール．ピー． シェーラー コーポレイション | 凍結乾燥された薬投与形状物の製造方法 |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| HUP0000393A3 (en) * | 1996-12-20 | 2000-12-28 | Nutrinova Gmbh | Method for increasing the sweetening power and enhancing the taste of a mixture of extremely powerful sweetening agents |
| US6471992B1 (en) | 1997-02-20 | 2002-10-29 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| EP1001748B1 (en) | 1997-07-25 | 2006-04-19 | Alpex Pharma S.A. | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| HUP0105089A3 (en) | 1998-11-20 | 2002-09-30 | Skyepharma Canada Inc | Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles |
| ATE289800T1 (de) | 1998-12-09 | 2005-03-15 | Chiron Corp | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| ES2292848T3 (es) | 2001-10-12 | 2008-03-16 | Elan Pharma International Limited | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. |
| US7993674B2 (en) | 2002-02-13 | 2011-08-09 | Weibel Michael K | Drug dose-form and method of manufacture |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| WO2005084377A2 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| JP2009521523A (ja) | 2005-12-27 | 2009-06-04 | ジュビラント・オルガノシス・リミテッド | 口中溶解性医薬組成物およびその製造方法 |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム． シーオー．， エルティーディー． | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
| US20110183942A1 (en) * | 2008-07-15 | 2011-07-28 | University Of Medicine And Dentistry Of New Jersey | Methods and Compositions for Treating Alzheimer's Disease |
| US8613937B2 (en) | 2008-10-31 | 2013-12-24 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| SI2727588T1 (sl) * | 2011-03-01 | 2019-03-29 | Pharnext | Na baklofenu in akamprosatu temelječa terapija nevroloških motenj |
| EA028060B1 (ru) * | 2011-07-13 | 2017-10-31 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
| IN2014DN07989A (enExample) | 2012-03-01 | 2015-05-01 | Pharnext | |
| EP3220890A1 (en) | 2014-11-21 | 2017-09-27 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| HRP20220208T1 (hr) * | 2015-03-03 | 2022-04-29 | Biohaven Therapeutics Ltd. | Prolijekovi riluzola i njihova primjena |
-
2015
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| PH12017500934B1 (en) | Sublingual formulation of riluzole | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| MX382608B (es) | Tratamiento del prurito urémico. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2016011706A (es) | Formulaciones de progesterona. | |
| MX2020011766A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| MA40574A (fr) | Traitement de maladies fibrotiques | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| UA104614U (uk) | Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| UA91619U (uk) | Спосіб підтримуючого лікування при генералізованому пародонтиті | |
| IN2014DE00822A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |